Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy
Advances in nanotechnology have provided novel avenues for the diagnosis and treatment of multiple myeloma (MM), a hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow. This review elucidates the potential of nanotechnology to revolutionize myeloma th...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/14/1/83 |
| _version_ | 1797344533017526272 |
|---|---|
| author | Min Yang Yu Chen Li Zhu Liangshun You Hongyan Tong Haitao Meng Jianpeng Sheng Jie Jin |
| author_facet | Min Yang Yu Chen Li Zhu Liangshun You Hongyan Tong Haitao Meng Jianpeng Sheng Jie Jin |
| author_sort | Min Yang |
| collection | DOAJ |
| description | Advances in nanotechnology have provided novel avenues for the diagnosis and treatment of multiple myeloma (MM), a hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow. This review elucidates the potential of nanotechnology to revolutionize myeloma therapy, focusing on nanoparticle-based drug delivery systems, nanoscale imaging techniques, and nano-immunotherapy. Nanoparticle-based drug delivery systems offer enhanced drug targeting, reduced systemic toxicity, and improved therapeutic efficacy. We discuss the latest developments in nanocarriers, such as liposomes, polymeric nanoparticles, and inorganic nanoparticles, used for the delivery of chemotherapeutic agents, siRNA, and miRNA in MM treatment. We delve into nanoscale imaging techniques which provide spatial multi-omic data, offering a holistic view of the tumor microenvironment. This spatial resolution can help decipher the complex interplay between cancer cells and their surrounding environment, facilitating the development of highly targeted therapies. Lastly, we explore the burgeoning field of nano-immunotherapy, which employs nanoparticles to modulate the immune system for myeloma treatment. Specifically, we consider how nanoparticles can be used to deliver tumor antigens to antigen-presenting cells, thus enhancing the body’s immune response against myeloma cells. In conclusion, nanotechnology holds great promise for improving the prognosis and quality of life of MM patients. However, several challenges remain, including the need for further preclinical and clinical trials to assess the safety and efficacy of these emerging strategies. Future research should also focus on developing personalized nanomedicine approaches, which could tailor treatments to individual patients based on their genetic and molecular profiles. |
| first_indexed | 2024-03-08T11:04:00Z |
| format | Article |
| id | doaj.art-2450d7793f4c4f919dca3e1cc3ada1cd |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-08T11:04:00Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-2450d7793f4c4f919dca3e1cc3ada1cd2024-01-26T15:19:33ZengMDPI AGBiomolecules2218-273X2024-01-011418310.3390/biom14010083Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma TherapyMin Yang0Yu Chen1Li Zhu2Liangshun You3Hongyan Tong4Haitao Meng5Jianpeng Sheng6Jie Jin7Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaZhejiang University Cancer Center, Hangzhou 310029, ChinaDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, ChinaAdvances in nanotechnology have provided novel avenues for the diagnosis and treatment of multiple myeloma (MM), a hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow. This review elucidates the potential of nanotechnology to revolutionize myeloma therapy, focusing on nanoparticle-based drug delivery systems, nanoscale imaging techniques, and nano-immunotherapy. Nanoparticle-based drug delivery systems offer enhanced drug targeting, reduced systemic toxicity, and improved therapeutic efficacy. We discuss the latest developments in nanocarriers, such as liposomes, polymeric nanoparticles, and inorganic nanoparticles, used for the delivery of chemotherapeutic agents, siRNA, and miRNA in MM treatment. We delve into nanoscale imaging techniques which provide spatial multi-omic data, offering a holistic view of the tumor microenvironment. This spatial resolution can help decipher the complex interplay between cancer cells and their surrounding environment, facilitating the development of highly targeted therapies. Lastly, we explore the burgeoning field of nano-immunotherapy, which employs nanoparticles to modulate the immune system for myeloma treatment. Specifically, we consider how nanoparticles can be used to deliver tumor antigens to antigen-presenting cells, thus enhancing the body’s immune response against myeloma cells. In conclusion, nanotechnology holds great promise for improving the prognosis and quality of life of MM patients. However, several challenges remain, including the need for further preclinical and clinical trials to assess the safety and efficacy of these emerging strategies. Future research should also focus on developing personalized nanomedicine approaches, which could tailor treatments to individual patients based on their genetic and molecular profiles.https://www.mdpi.com/2218-273X/14/1/83multiple myelomananotechnologynanoparticle-based drug deliverynano-immunotherapy |
| spellingShingle | Min Yang Yu Chen Li Zhu Liangshun You Hongyan Tong Haitao Meng Jianpeng Sheng Jie Jin Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy Biomolecules multiple myeloma nanotechnology nanoparticle-based drug delivery nano-immunotherapy |
| title | Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy |
| title_full | Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy |
| title_fullStr | Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy |
| title_full_unstemmed | Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy |
| title_short | Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy |
| title_sort | harnessing nanotechnology emerging strategies for multiple myeloma therapy |
| topic | multiple myeloma nanotechnology nanoparticle-based drug delivery nano-immunotherapy |
| url | https://www.mdpi.com/2218-273X/14/1/83 |
| work_keys_str_mv | AT minyang harnessingnanotechnologyemergingstrategiesformultiplemyelomatherapy AT yuchen harnessingnanotechnologyemergingstrategiesformultiplemyelomatherapy AT lizhu harnessingnanotechnologyemergingstrategiesformultiplemyelomatherapy AT liangshunyou harnessingnanotechnologyemergingstrategiesformultiplemyelomatherapy AT hongyantong harnessingnanotechnologyemergingstrategiesformultiplemyelomatherapy AT haitaomeng harnessingnanotechnologyemergingstrategiesformultiplemyelomatherapy AT jianpengsheng harnessingnanotechnologyemergingstrategiesformultiplemyelomatherapy AT jiejin harnessingnanotechnologyemergingstrategiesformultiplemyelomatherapy |